What records are connected here?
- Evidence lanes
- 3
- Source years
- 6
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Limited human dataCancer
Gallium Ga 68 dotatate is a radioactive imaging agent: dotatate, a cyclic eight-amino-acid peptide that binds somatostatin receptors, carrying the positron-emitting isotope gallium-68.1 FDA approved the NETSPOT kit, which is used to prepare it, in 2016 for PET scans to locate somatostatin receptor-positive neuroendocrine tumors in adults and children.1,2 Approval rests on three open-label imaging studies. The label has no boxed warning and notes that it adds to a person’s long-term radiation exposure.1
| What it is | Dotatate (DOTA-Tyr3-octreotate), a cyclic eight-amino-acid peptide with a bound chelator, labelled with gallium-68 for PET imaging, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists NETSPOT, NDA 208547, with an original approval date of June 1, 2016. The label has no boxed warning.1,2 |
| Human evidence | Three open-label, single-centre imaging studies in 97, 104 and 63 people with known or suspected neuroendocrine tumors, described in the label.1 |
| Evidence strength | Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned |
Dotatate, also known as DOTA-Tyr3-octreotate, is a cyclic peptide of eight amino acids joined to a chelator, DOTA, that holds a radioactive metal. Labelled with gallium-68, it becomes gallium Ga 68 dotatate, according to the label.1
In the United States it is prepared from the NETSPOT kit, approved under NDA 208547, according to Drugs@FDA.2
It binds to somatostatin receptors, most strongly to subtype 2, which many neuroendocrine tumor cells carry in large numbers. Gallium-68 emits positrons, so a PET scanner can show where it has collected, according to the label.1
In one study of 97 adults with known or suspected neuroendocrine tumors, scans were read by two blinded readers; among 50 patients with tumors found on CT or MRI, the gallium Ga 68 dotatate scan was positive in 48.1
In a second study of 104 patients, scans correctly found a tumor site in 29 of 36 patients with confirmed tumors and were falsely positive in 7 of 68 without. A third study, of 63 patients checked for recurrence, gave similar results, according to the label.1
Evidence-strength label: Limited human data. How this label is assigned
Yes. Drugs@FDA lists NETSPOT, NDA 208547, with an original approval date of June 1, 2016.2
The NETSPOT label cited here (DailyMed SPL version 23, published July 7, 2026) states that, after radiolabeling with gallium-68, it is indicated for use with PET to locate somatostatin receptor-positive neuroendocrine tumors in adults and children.1
The label has no boxed warning. It warns that it adds to a patient’s long-term cumulative radiation exposure, and describes hypersensitivity reactions, mostly rash and itching.1
How often it misses tumors or flags tumors that are not there in wider use: in the label’s second study, scans missed a confirmed tumor in 7 of 36 patients.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Gallium Ga 68 dotatate: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Gallium Ga 68 dotatate are a bounded selection, not every registration or paper about Gallium Ga 68 dotatate. For the years before Gallium Ga 68 dotatate was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Gallium Ga 68 dotatate as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Gallium Ga 68 dotatate in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as NETSPOT for PET imaging of neuroendocrine tumors. Approval rests on three open-label imaging studies in 97, 104 and 63 people. The label has no boxed warning and notes added radiation exposure.↗↗
Status sources checked through November 16, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as NETSPOT for PET imaging of neuroendocrine tumors. Approval rests on three open-label imaging studies in 97, 104 and 63 people. The label has no boxed warning and notes added radiation exposure.↗↗
The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date October 26, 2026
ClinicalTrials.gov record NCT03206060↗Added to PeptideScanner November 16, 2026Regulatory · added November 17, 2026
Drugs@FDA application NDA208547↗Source date June 1, 2016Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT03206060↗Source date October 26, 2026Literature metadata · added November 16, 2026
Pulmonary Metastasis of Grade 1 Meningioma Mimicking a Carcinoid Tumor: A Case Report with FDG PET/CT, Ga-68 DOTATATE PET/CT, and Pathological Confirmation.↗Source date September 26, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
5 of 6 selected trial records include at least one phase value; 6 of 6 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
6 of 6 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
The official Drugs@FDA dataset lists original submission 1 for NDA 208547 with status AP dated 2016-06-01, and names gallium dotatate ga-68 among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT03206060 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT03448458 at 2026-11-16T17:36:42.191Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
6 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
Selected records span June 1, 2016 to October 26, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03206060 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗
Literature metadata
PubMed lists PMID 42787917 in World journal of nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2026-05-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07150806 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04040088 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04069299 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03448458 at 2026-11-16T17:36:42.191Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗
Literature metadata
PubMed lists PMID 38262470 in Nuklearmedizin. Nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2024-01-23 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38967895 in The international journal of cardiovascular imaging as Journal Article, Validation Study, Comparative Study, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38933071 in World journal of nuclear medicine as Journal Article, with publication-date metadata of 2024-05-07 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38563291 in Journal of medical imaging and radiation oncology as Journal Article, with publication-date metadata of 2024-04-02 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03953131 at 2026-11-16T17:36:42.191Z. Its registry update date was 2023-09-01, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗
Literature metadata
PubMed lists PMID 34096898 in Topics in magnetic resonance imaging : TMRI as Journal Article, Review, with publication-date metadata of 2021-06-01 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026